Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | IL1RN | P18510 | 4/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880387 | 1.00 | NMBR (0.53) | NMBRKMT2AMEN1TLR2HCRTR1 | |
| SCHEMBL4880375 | 1.00 | NMBR (0.53) | NMBRKMT2AMEN1TLR2HCRTR1 | |
| SCHEMBL30449054 | 0.92 | NMBR (0.55) | NMBRTLR2GHSRSIRT5 | |
| SCHEMBL31405559 | 0.92 | NMBR (0.55) | NMBRTLR2GHSRSIRT5 | |
| SCHEMBL30448384 | 0.92 | NMBR (0.55) | NMBRTLR2GHSRSIRT5 | |
| SCHEMBL31405549 | 0.92 | NMBR (0.55) | NMBRTLR2GHSRSIRT5 | |
| SCHEMBL29372872 | 0.91 | NMBR (0.55) | NMBRTLR2GHSRSIRT5 | |
| SCHEMBL12513472 | 0.91 | SIRT5 (0.53) | NMBRGHSRSIRT5IL1RNERAP2 | |
| SCHEMBL30074815 | 0.89 | KMT2A (0.58) | NMBRKMT2AMEN1HCRTR1NPBWR1 | |
| SCHEMBL31405551 | 0.89 | NMBR (0.52) | NMBRGHSRSIRT5IL1RNERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | NMBR 2134/4885KMT2A 3406/4885MEN1 4687/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | NMBR 3131/4885KMT2A 1805/4885MEN1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.